Table 2.
Adverse events of grades 3–5.
| Studies |
Sample Size (LD/HD) |
Radiation Technology |
Radiotherapy Dose | Pneumonitis | Esophagitis |
Treatment-Related Death |
Evaluation Criterion for Toxicities |
|
|---|---|---|---|---|---|---|---|---|
| LD-RT | HD-RT | |||||||
| (11) | 24/20 | IMRT | 60 Gy/2 Gy | 63.9 Gy/2.27 Gy | 0 vs. 0 | 0 vs. 0 | 0 vs. 0 | CTCAE 3.0 |
| (12) | 60/83 | 3D-CRT | 38–50.4 Gy/1.8–2 Gy | 50.7–72 Gy/1.8–2.5 Gy | 0 vs. 0 | 6.8 vs. 8.4% | 0 vs. 0 | CTCAE 3.0 |
| (13) | 137/56 | 3D-CRT/IMRT | 41.4–50.4 Gy/1.6–2.4 Gy | 52.2–66 Gy/1.6–2.4 Gy | 6.6% vs. 0 | 20.4 vs. 17.9% | 5.1 vs. 3.6% | CTCAE 3.0 |
| (17) | 63/74 | 3D-CRT/IMRT | 50–50.4 Gy/1.8–2 Gy | ≥59.4 Gy/1.8–2 Gy | 4.0 vs. 6.0% | 2.2 vs. 10.5% | 3.2 vs. 6.8% | CTCAE 3.0 |
| (18) | 120/116 | 3D-CRT/IMRT/ TOMO | <60 Gy/1.8–2 Gy | ≥60 Gy/1.8–2 Gy | 2.5% vs. 0 | 6.7 vs. 6.0% | 1.7 vs. 0.9% | CTCAE 4.0 |
| (19) | 42/42 | IMRT/VMAT | 44–50.4 Gy/– | 52.2–70 Gy/– | 0 vs. 0 | 0 vs. 0 | 0 vs. 0 | CTCAE 4.0 |
| (20) | 190/190 | 3D-CRT/IMRT | 50.4–54 Gy/1.8 Gy | 60 Gy/2 Gy | 1.6 vs. 1.6% | 2.6 vs. 7.4% | 0.5 vs. 3.2% | CTCAE 4.0 |
| (21) | 43/37 | 3D-CRT/IMRT | 50.4–56 Gy/1.8–2 Gy | 59.4–64.8 Gy/1.8–2 Gy | 9.3 vs. 27.0% | 9.3 vs. 21.6% | 0 vs. 0 | CTCAE 4.0 |
LD, low dose; HD, high dose; RT, radiotherapy; 3DRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; VMAT, volume-modulated arc therapy; TOMO, helical tomotherapy; LD-RT vs. HD-RT group; CTCAE, Common Terminology Criteria for Adverse Events.